The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Real-world Strangvac data shows nearly 100% protection
Intervacc AB (publ) today announces that after the first 100.000 doses of Strangvac® were sold in the EU and UK, only 3 cases of confirmed S. equi infection were reported in horses that completed their primary vaccination. Strangles, a potentially lethal infection...Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials
Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, has completed the evaluation of a US strain of Streptococcus equi in US horses prior to its use in a clinical trial towards the registration of Strangvac®, a vaccine against equine...Emil Billbäck appointed new Chair of the Board of Intervacc
Intervacc AB (publ), a growth company within veterinary medicine with its vaccine Strangvac® registered in 16 European countries, today announces that Chairman of the Board Håkan Björklund has handed over to Emil Billbäck, previously a Board member, who was elected as...Report from Annual General Meeting in Intervacc
Intervacc AB (publ) held its Annual General Meeting (”AGM”) on Wednesday 13 May 2026, at which the following resolutions were made. Adoption of the income statement and balance sheet The AGM adopted the Board of Directors’ submitted income statement and balance sheet...Nyhetstjänster
